469 related articles for article (PubMed ID: 32251497)
1. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.
Lachowiez CA; Loghavi S; Kadia TM; Daver N; Borthakur G; Pemmaraju N; Naqvi K; Alvarado Y; Yilmaz M; Short N; Ohanian M; Pierce SR; Patel KP; Qiao W; Ning J; Sasaki K; Takahashi K; Jabbour E; Andreeff M; Ravandi F; Kantarjian HM; Konopleva M; DiNardo CD
Blood Adv; 2020 Apr; 4(7):1311-1320. PubMed ID: 32251497
[TBL] [Abstract][Full Text] [Related]
2. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
Maiti A; Qiao W; Sasaki K; Ravandi F; Kadia TM; Jabbour EJ; Daver NG; Borthakur G; Garcia-Manero G; Pierce SA; Montalbano KS; Pemmaraju N; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Takahashi K; Yilmaz M; Jain N; Kornblau SM; Andreeff M; Bose P; Ferrajoli A; Issa GC; Masarova L; Thompson PA; Rausch CR; Ning J; Kantarjian HM; DiNardo CD; Konopleva MY
Am J Hematol; 2021 Mar; 96(3):282-291. PubMed ID: 33264443
[TBL] [Abstract][Full Text] [Related]
3. Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study.
Weng G; Huang J; He X; Xue T; Yang L; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Jin H; Liu Q; Du X
Ann Hematol; 2023 Dec; 102(12):3369-3381. PubMed ID: 37723307
[TBL] [Abstract][Full Text] [Related]
4. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.
Weng G; Zhang Y; Yu G; Luo T; Yu S; Xu N; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Shao R; Du X; Jin H; Liu Q
J Intern Med; 2023 Mar; 293(3):329-339. PubMed ID: 36284445
[TBL] [Abstract][Full Text] [Related]
5. Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
Daver NG; Iqbal S; Renard C; Chan RJ; Hasegawa K; Hu H; Tse P; Yan J; Zoratti MJ; Xie F; Ramsingh G
J Hematol Oncol; 2023 Mar; 16(1):19. PubMed ID: 36879351
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
[TBL] [Abstract][Full Text] [Related]
7. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Shimony S; Bewersdorf JP; Shallis RM; Liu Y; Schaefer EJ; Zeidan AM; Goldberg AD; Stein EM; Marcucci G; Lindsley RC; Chen EC; Ramos Perez J; Stein A; DeAngelo DJ; Neuberg DS; Stone RM; Ball B; Stahl M
Leukemia; 2024 Apr; 38(4):762-768. PubMed ID: 38378841
[TBL] [Abstract][Full Text] [Related]
8. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
Maiti A; DiNardo CD; Qiao W; Kadia TM; Jabbour EJ; Rausch CR; Daver NG; Short NJ; Borthakur G; Pemmaraju N; Yilmaz M; Alvarado Y; Montalbano KS; Wade A; Maduike RE; Guerrero JA; Vaughan K; Bivins CA; Pierce S; Ning J; Ravandi F; Kantarjian HM; Konopleva MY
Cancer; 2021 Nov; 127(22):4213-4220. PubMed ID: 34343352
[TBL] [Abstract][Full Text] [Related]
9. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
Venugopal S; Shoukier M; Konopleva M; Dinardo CD; Ravandi F; Short NJ; Andreeff M; Borthakur G; Daver N; Pemmaraju N; Sasaki K; Montalban-Bravo G; Marx KR; Pierce S; Popat UR; Shpall EJ; Kanagal-Shamanna R; Garcia-Manero G; Kantarjian HM; Kadia TM
Cancer; 2021 Oct; 127(19):3541-3551. PubMed ID: 34182597
[TBL] [Abstract][Full Text] [Related]
10. Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis.
Sutter T; Schittenhelm M; Volken T; Lehmann T
Hematology; 2023 Dec; 28(1):2206694. PubMed ID: 38078486
[TBL] [Abstract][Full Text] [Related]
11. Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia.
Jin D; Chen H; He J; Li Y; Zheng G; Yang Y; Zhao Y; Le J; Shu W; He D; Cai Z
Target Oncol; 2024 Mar; 19(2):237-249. PubMed ID: 38466536
[TBL] [Abstract][Full Text] [Related]
12. Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy.
Weng G; Huang J; An N; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; He X; Jin H; Liu Q; Du X
Cancer Med; 2024 Jan; 13(2):e6885. PubMed ID: 38334500
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study.
Xin F; Yu YH; Shen XL; Zhang GX
Hematology; 2024 Dec; 29(1):2350319. PubMed ID: 38748459
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
Gangat N; Karrar O; Iftikhar M; McCullough K; Johnson IM; Abdelmagid M; Abdallah M; Al-Kali A; Alkhateeb HB; Begna KH; Mangaonkar A; Saliba AN; Hefazi Torghabeh M; Litzow MR; Hogan W; Shah M; Patnaik MM; Pardanani A; Badar T; Murthy H; Foran J; Palmer J; Sproat L; Khera N; Arana Yi C; Tefferi A
Am J Hematol; 2024 Feb; 99(2):193-202. PubMed ID: 38071734
[TBL] [Abstract][Full Text] [Related]
15. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.
Lachowiez CA; Loghavi S; Furudate K; Montalban-Bravo G; Maiti A; Kadia T; Daver N; Borthakur G; Pemmaraju N; Sasaki K; Alvarado Y; Yilmaz M; Short NJ; Chien K; Ohanian M; Pierce S; Patel KP; Jabbour E; Ravandi F; Kantarjian HM; Garcia-Manero G; Takahashi K; Konopleva MY; DiNardo CD
Blood Adv; 2021 Apr; 5(8):2173-2183. PubMed ID: 33885753
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of European LeukemiaNet 2022 criteria and genomic clusters using machine learning in older adults with acute myeloid leukemia.
Park S; Kim TY; Cho BS; Kwag D; Lee JM; Kim M; Kim Y; Koo J; Raman A; Kim TK; Kim HJ
Haematologica; 2024 Apr; 109(4):1095-1106. PubMed ID: 37706344
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
Abaza Y; Winer ES; Murthy GSG; Shallis RM; Matthews AH; Badar T; Geramita EM; Kota VK; Swaroop A; Doukas P; Bradshaw D; Helenowski IB; Liu Y; Zhang H; Im A; Litzow MR; Perl AE; Atallah E; Altman JK
Am J Hematol; 2024 Apr; 99(4):606-614. PubMed ID: 38342997
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.
Cherry EM; Abbott D; Amaya M; McMahon C; Schwartz M; Rosser J; Sato A; Schowinsky J; Inguva A; Minhajuddin M; Pei S; Stevens B; Winters A; Jordan CT; Smith C; Gutman JA; Pollyea DA
Blood Adv; 2021 Dec; 5(24):5565-5573. PubMed ID: 34610123
[TBL] [Abstract][Full Text] [Related]
19. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.
Short NJ; Venugopal S; Qiao W; Kadia TM; Ravandi F; Macaron W; Dinardo CD; Daver N; Konopleva M; Borthakur G; Shpall EJ; Popat U; Champlin RE; Mehta R; Al-Atrash G; Oran B; Jabbour E; Garcia-Manero G; Issa GC; Montalban-Bravo G; Yilmaz M; Maiti A; Kantarjian H
J Hematol Oncol; 2022 Jan; 15(1):12. PubMed ID: 35093134
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia.
Liang P; Xie Y; Liu Z; Wang D; Li Q; Lu Y; Xue S; Wang Y; Chen S; Wu D; Fu J
Br J Haematol; 2024 Apr; 204(4):1219-1226. PubMed ID: 38180132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
